Microcap pharmaceutical development company Gardant Pharmaceuticals Inc. is hoping buyers will find its slimmed-down operations attractive. The $20 million market cap company announced on June 7 it is exploring a sale in the midst of spinning off several of its units into independent companies.
To read the entire story, you must be logged in.
Please log in now or register with us.
